Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $66.81 USD
Change Today +0.19 / 0.29%
Volume 418.2K
ABBV On Other Exchanges
Symbol
Exchange
New York
EN Paris
Mexico
Frankfurt
As of 9:44 AM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).

abbvie inc (ABBV) Snapshot

Open
$66.90
Previous Close
$66.93
Day High
$67.18
Day Low
$66.62
52 Week High
12/8/14 - $70.76
52 Week Low
08/6/14 - $51.37
Market Cap
117.3B
Average Volume 10 Days
15.0M
EPS TTM
$3.32
Shares Outstanding
1.8B
EX-Date
04/13/15
P/E TM
20.2x
Dividend
$2.04
Dividend Yield
2.76%
Current Stock Chart for ABBVIE INC (ABBV)

abbvie inc (ABBV) Details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.

26,000 Employees
Last Reported Date: 05/8/15
Founded in 2012

abbvie inc (ABBV) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.6M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $923.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $1.5M
Executive Vice President of Commercial Operat...
Total Annual Compensation: $844.5K
Executive Vice President of Business Developm...
Total Annual Compensation: $957.6K
Compensation as of Fiscal Year 2014.

abbvie inc (ABBV) Key Developments

AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib

AbbVie announced findings from a Phase 2 study of the investigational medicine veliparib combined with the chemotherapy regimen carboplatin and paclitaxel that showed an improvement in median progression-free survival (PFS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC) who are current smokers. These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1 in Chicago. Veliparib is an investigational oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor being evaluated for the treatment of various cancer types, including NSCLC. Lung cancer patients who are current smokers are at a higher risk of death than non-smokers. Tobacco use accounts for at least 30% of all cancer deaths, causing 87% of lung cancer deaths in men, and 70% of lung cancer deaths in women. These data suggest smoking status may influence efficacy for veliparib-chemotherapy combination in advanced NSCLC. A Phase 3 study has been initiated in NSCLC patients with smoking history based on the results seen in the Phase 2 study.

AbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma At the American Society of Clinical Oncology Annual Meeting

AbbVie announced that results from a Phase 1b trial of investigational venetoclax, a novel inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, in combination with bortezomib and dexamethasone, showed an 83 percent overall response rate (n=5/6) in bortezomib-naive patients with relapsed/refractory (R/R) multiple myeloma, including two patients who achieved complete responses.1 These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31, in Chicago. AbbVie will also present during ASCO a separate Phase 1 monotherapy study in heavily pre-treated patients with R/R multiple myeloma, which showed an overall response rate of 29% (n=2/7) in patients with t(11;14) chromosomal abnormality. Multiple myeloma is the second most common blood cancer and begins in plasma cells in the bone marrow. When plasma cells in the marrow become cancerous, they can grow uncontrollably and form tumors, typically developing in the bone. When a patient has multiple plasma cell tumors, they have multiple myeloma. Investigation of venetoclax in several additional blood cancers is currently ongoing.

AbbVie Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015

AbbVie Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Presentation Date & Speakers: May-29-2015, David Donabedian, Vice President & Head, Ventures and Early Stage Collaborations, Margarita Chavez, Director, Ventures & Early Stage Collaborations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABBV:US $66.81 USD +0.19

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.09 USD +0.15
Amgen Inc $156.87 USD +0.43
Bristol-Myers Squibb Co $65.74 USD -0.06
Eli Lilly & Co $78.11 USD +0.16
Medtronic PLC $76.77 USD -0.11
View Industry Companies
 

Industry Analysis

ABBV

Industry Average

Valuation ABBV Industry Range
Price/Earnings 59.6x
Price/Sales 5.2x
Price/Book 77.4x
Price/Cash Flow 58.7x
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit www.abbvie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.